Results 51 to 60 of about 12,862 (201)

Comparative histological study on the possible protective effect of Mitoquinone versus Oxymatrine on cerebellar cortex of adult male albino rats treated with Sofosbuvir [PDF]

The Egyptian Journal of Histology
:Background: Chronic hepatitis C is worldwide public-health issue. It is considered main cause for liver-related morbidity and mortality. Sofosbuvir, a direct-acting antiviral drug has revolutionized HCV treatment with high success rate.
Mona Soliman, Rania Emara, Dalia Noya
doaj   +1 more source

ProTides for Antiviral Activity Beyond Liver Cells

Chemistry – A European Journal, Volume 32, Issue 21, 1 June 2026.
A strategy for obtaining prodrugs of antiviral nucleotides with broad tissue activity is presented that relies on cycloalkyl or cycloalkylalkyl esters, improving uptake and esterase cleavage, and producing nanomolar inhibitors in kidney, colon, and lung cells.
Felix Goebel, Adrian Humboldt, Heeyoung Kim, Carl J. M. Schölzel, Ralf Bartenschlager, Clemens Richert   +5 more
wiley   +1 more source

Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis [PDF]

, 2018
INTRODUCTION: Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue antiviral drug that has shown remarkable efficacy in the treatment of hepatitis C in clinical trials.
Duarte, MM, Sterrantino, C, Barra, M, Gonçalves, N, Ferreira, JJ, Rodrigues, FB, Pinto, FJ, Costa, J, Caldeira, D   +8 more
core  

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Pakistan Armed Forces Medical Journal, 2021
Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study.
Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique   +5 more
doaj   +1 more source

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease

Viruses, 2022
Background: Hepatitis C virus (HCV) is still common in patients with chronic kidney disease. It has been recently discovered that chronic HCV is a risk factor for increased incidence of CKD in the adult general population.
Fabrizio Fabrizi, Federica Tripodi, Roberta Cerutti, Luca Nardelli, Carlo M. Alfieri, Maria F. Donato, Giuseppe Castellano   +6 more
doaj   +1 more source

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis

, 2017
© Springer International Publishing AG 2017Introduction: Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue antiviral drug that has shown remarkable efficacy in the treatment of hepatitis C in clinical trials.
João Costa, Ferreira, Joaquim J, Duarte, Marta M., Fausto J. Pinto, Barra, Márcio, Costa, João, Filipe B. Rodrigues, Nilza Gonçalves, Daniel Caldeira, Marta M. Duarte, Rodrigues, Filipe B., Joaquim J. Ferreira, Sterrantino, Carmelo, Rodrigues, Filipe Brogueira, Márcio Barra, Caldeira, Daniel, Gonçalves, Nilza, Pinto, Fausto J., Carmelo Sterrantino   +18 more
core   +1 more source

The effects of sofosbuvir-based treatment of hepatitis C virus on patients with chronic obstructive pulmonary disease

Egyptian Journal of Chest Disease and Tuberculosis, 2020
Background To date, no sufficient reports have studied the effects of sofosbuvir-based hepatitis C virus (HCV) treatment regimens on chronic obstructive pulmonary disease(COPD) exacerbation.
Ahmad Abbas, Ahmed A Abdelmoaty, Ahmed M El-Gebaly, Maha E Alsadik   +3 more
doaj   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source